

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



CIP2A Monoclonal Antibody [2A1-9A4]





Mouse Monoclonal

Purified RefSeq ID NP_065941.1

Catalog No. A500-010ACF Uniprot ID Q8TCG1

Lot No. A500-010ACF-2

APPLICATIONS WB, IP

SPECIES REACTIVITY Human, Mouse

AMOUNT 100 μl

CONCENTRATION 1000 μg/ml

STORAGE/SHELF LIFE 2 - 8°C / 1 year from date of receipt

PHYSICAL STATE Liquid

BUFFER Tris-buffered Saline containing 0.09% Sodium Azide, BSA Free

ISOTYPE IgG1-kappa
CLONE # 2A1-9A4

ORIGIN USA

PRODUCTION The immunogen was the amino terminal one-third of the CIP2A (GeneID 57650)

PROCEDURES recombinant protein.

The hybridoma was grown in a bioreactor and the antibody was purified using a mouse

immunoglobulin binding ligand.

APPLICATIONS Centrifuge tube to remove product from lid. Optimal working dilutions should be determined

experimentally by the investigator. Prepare working dilution immediately before use.

APPLICATION NOTES

A500-010ACF is the carrier-free version of A500-010, which is qualified for use in Western

Blot, Immunoprecipitation, Immunohistochemistry, and/or Immunocytochemistry. The format of A500–010ACF is designed for compatibility with the labeling of the antibody such as with fluorochromes, metal isotopes, oligonucleotides, and enzymes. Upon completion of labeling, the user must empirically define the assay dependent concentration for use.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.

Michael Spencer, PhD

Date: September 29, 2022